OncoSec Secures Rights For Cliniporator Gene Electrotransfer Platform Developed By IGEA

OncoSec Medical Inc. (ONCS) said Tuesday that it has licensed the exclusive rights to the Cliniporator electroporation or gene electrotransfer platform from IGEA Clinical Biophysics.

The license encompasses a broad field of use for gene delivery in oncology, including use as part of OncoSec's visceral lesion applicator program.

The U.S. Food and Drug Administration has cleared the Cliniporator platform for use in the upcoming Phase 1 trial to be held at Providence Health investigating CORVax12, the company's DNA-encodable vaccine candidate for COVID-19.

CORVax12 combines TAVO, a DNA plasmid-based interleukin-12, with the National Institute of Health's SARS-CoV-2 virus "spike" protein.

In Tuesday regular trading, ONCS was trading at $5.41 up $0.19 or 3.66 percent.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The National Restaurant Association or NRA has urged the U.S. Congress to refill the Restaurant Revitalization Fund or RRF, which is expected to save more than 1.6 million jobs in the restaurant industry hit hard by the surge in Omicron Variant. In a letter to Congress, the association highlighted, based on its survey on 4,200 restaurant operators, the devastating impact so far on the industry... Industrial conglomerate General Electric Co. reported Tuesday a net loss for the fourth quarter compared to a profit last year, hurt by steep debt extinguishment costs and lower revenues. However, adjusted earnings per share topped analysts' expectations, while quarterly revenues missed them. Shares of LM Ericsson were gaining more than 7 percent in Swedish trading as well as in pre-market activity on Nasdaq, after the telecom equipment maker reported Tuesday higher profit and sales in its fourth quarter with strong demand. Further, the company lifted its full-year dividend, and maintained targets for fiscal 2022 EBIT growth as well as long-term target of EBITA margin.
Follow RTT